Steven Pennybaker1, Brian J Roach2, Susanna L Fryer1,2, Anusha Badathala2, Art W Wallace2,3, Daniel H Mathalon1,2, Tobias F Marton4,5,6. 1. Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA. 2. San Francisco VA Health Care System, San Francisco, USA. 3. Department of Anesthesiology, University of California, San Francisco, USA. 4. Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, USA. tobias.marton@ucsf.edu. 5. San Francisco VA Health Care System, San Francisco, USA. tobias.marton@ucsf.edu. 6. San Francisco VA Health Care System/Mental Health Service (116D), 4150 Clement Street, CA, 94121, San Francisco, USA. tobias.marton@ucsf.edu.
Abstract
RATIONALE: Ketamine is a novel, rapid-acting antidepressant for treatment refractory depression (TRD); however, clinical durability is poor and treatment response trajectories vary. Little is known about which patient characteristics predict faster or more durable ketamine responses. Ketamine's antidepressant mechanism may involve modulation of glutamatergic signaling and long-term potentiation (LTP); these neuroplasticity pathways are also attenuated with older age. OBJECTIVE: A retrospective analysis examining the impact of patient age on the speed and durability of ketamine's antidepressant effects in 49 veterans receiving serial intravenous ketamine infusions for TRD. METHOD: The relationship between age and percent change in Beck Depression Inventory (BDI-II) scores was compared across six serial ketamine infusions (twice-weekly for 3 weeks) using a linear-mixed model. RESULTS: A significant Age-X-Infusion number interaction (F = 3.01, p = .0274) indicated that the relationship between age and treatment response depended on infusion number. Follow-up tests showed that younger age significantly predicted greater clinical improvement at infusion #4 (t = 3.02, p = .004); this relationship was attenuated at infusion #5 (t = 1.95, p = .057) and was absent at infusion #6. Age was not a significant predictor of treatment durability, defined as percent change in BDI-II 3 weeks following infusion #6. CONCLUSIONS: These data preliminarily suggest that younger age is associated with a faster response over six serial ketamine infusions; by infusion #6 and subsequent weeks of clinical follow-up, age no longer predicts ketamine's antidepressant activity. Age may mediate the speed but not the durability or total efficacy of ketamine treatment, suggesting that dissociable mechanisms may underlie differing aspects of ketamine's antidepressant activity.
RATIONALE: Ketamine is a novel, rapid-acting antidepressant for treatment refractory depression (TRD); however, clinical durability is poor and treatment response trajectories vary. Little is known about which patient characteristics predict faster or more durable ketamine responses. Ketamine's antidepressant mechanism may involve modulation of glutamatergic signaling and long-term potentiation (LTP); these neuroplasticity pathways are also attenuated with older age. OBJECTIVE: A retrospective analysis examining the impact of patient age on the speed and durability of ketamine's antidepressant effects in 49 veterans receiving serial intravenous ketamine infusions for TRD. METHOD: The relationship between age and percent change in Beck Depression Inventory (BDI-II) scores was compared across six serial ketamine infusions (twice-weekly for 3 weeks) using a linear-mixed model. RESULTS: A significant Age-X-Infusion number interaction (F = 3.01, p = .0274) indicated that the relationship between age and treatment response depended on infusion number. Follow-up tests showed that younger age significantly predicted greater clinical improvement at infusion #4 (t = 3.02, p = .004); this relationship was attenuated at infusion #5 (t = 1.95, p = .057) and was absent at infusion #6. Age was not a significant predictor of treatment durability, defined as percent change in BDI-II 3 weeks following infusion #6. CONCLUSIONS: These data preliminarily suggest that younger age is associated with a faster response over six serial ketamine infusions; by infusion #6 and subsequent weeks of clinical follow-up, age no longer predicts ketamine's antidepressant activity. Age may mediate the speed but not the durability or total efficacy of ketamine treatment, suggesting that dissociable mechanisms may underlie differing aspects of ketamine's antidepressant activity.
Authors: R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal Journal: Biol Psychiatry Date: 2000-02-15 Impact factor: 13.382
Authors: Brian R Cornwell; Giacomo Salvadore; Maura Furey; Craig A Marquardt; Nancy E Brutsche; Christian Grillon; Carlos A Zarate Journal: Biol Psychiatry Date: 2012-04-21 Impact factor: 13.382
Authors: David L Dunner; A John Rush; James M Russell; Michael Burke; Stacy Woodard; Peggy Wingard; John Allen Journal: J Clin Psychiatry Date: 2006-05 Impact factor: 4.384
Authors: Joshua C Brown; William H DeVries; Jeffrey E Korte; Gregory L Sahlem; Leonardo Bonilha; E Baron Short; Mark S George Journal: Brain Stimul Date: 2020-01-08 Impact factor: 8.955
Authors: Chadi G Abdallah; Lynnette A Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Mohamed Sherif; Kyung-Heup Ahn; Deepak Cyril D'Souza; Richard Formica; Steven M Southwick; Ronald S Duman; Gerard Sanacora; John H Krystal Journal: Neuropsychopharmacology Date: 2020-02-24 Impact factor: 7.853
Authors: Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678
Authors: Alessia Mastrodonato; Ina Pavlova; Noelle Kee; Josephine C McGowan; J John Mann; Christine A Denny Journal: Front Neurosci Date: 2022-04-21 Impact factor: 4.677